[Correspondence] Anti-PD-1 antibody treatment for melanoma

Beaver and colleagues1 reported on the rate of radiographic response after documented disease progression by studying a pooled analysis of individual patient data provided to the US Food and Drug Administration in support of the approval of anti-programmed death receptor-1 (PD-1) therapies for patients with advanced melanoma. Defining this rate is of high importance when interpreting clinical trials of a combination of anti-PD-1 antibodies with another agent in the population of patients who did not respond to prior anti-PD-1 therapy.

Source: The Lancet Oncology - April 26, 2018 Category: Cancer & Oncology Authors: Antoni Ribas, John M Kirkwood, Keith T Flaherty Tags: Correspondence Source Type: research